Nasdaq: AKTS · Listed Jan 9, 2026
Aktis Oncology IPO
IPO price
$18.00
Aktis Oncology (AKTS) priced its IPO at $18.00 a share and has traded on Nasdaq since Jan 9, 2026.
AKTS today$16.10-10.56%since IPO15-min delayed · as of 4:12:59 AM EST on Nov 19, 2026
See the AKTS quoteFirst trading day · Jan 9, 2026
- IPO price
- $18.00
- the top of the range of $16 to $18
- First trade
- $27.00
- +50.00% from the IPO price
- First-day last trade
- $22.19
- +23.26% from the IPO price, regular session
- Raise
- $317.7M
- before the underwriters' option
These numbers are from the first trading day, Jan 9, 2026.
How AKTS did against the market
AKTS against the market, from its first trade at 11:10 ET to the last trade of the session.
- AKTS from its first trade
- -17.83%
- Against the market (QQQ)
- -18.0 pts
AKTS fell 17.8% from its first trade to the last trade of the session. That is 18.0 points worse than the market.
Same-day moves do not show that AKTS caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
AKTS against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
AKTS against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Aktis Oncology '26 | $317.7M | +50.00% | +23.26% | +13.75% | +7.83% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Aktis Oncology IPO offers 17.65M shares to raise $317.7M, before any underwriters' option.
- Expected price range
- $16 to $18
- IPO price
- $18.00
- Shares offered
- 17.65M
- Money raised
- $317.7M
- Listing date
- Jan 9, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Aktis Oncology$317.7M
Where AKTS ranks
Aktis Oncology's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- AKTS$898.35M
AKTS news
The latest news and headlines about Aktis Oncology (AKTS).
- Does Aktis (AKTS) Have the Potential to Rally 105.62% as Wall Street Analysts Expect?positiveZacks Investment Research· Nov 11, 2026
- Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer CompanypositiveThe Motley Fool· May 13, 2026
- Aktis Oncology to Present at the BofA Securities Health Care ConferencepositiveGlobeNewswire Inc.· May 6, 2026
- Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingpositiveGlobeNewswire Inc.· Apr 21, 2026
- A Fresh IPO That Long-Term Investors Shouldn’t IgnorepositiveInvesting.com· Jan 14, 2026
- Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional SharespositiveBenzinga· Jan 13, 2026
Filings and the company
What Aktis Oncology has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Aktis Oncology discloses to the SEC on Form 8-K.
- Quarterly earningsNov 12, 2026
On November 12, 2026, Aktis Oncology, Inc. issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2026.
- Director departureApr 16, 2026
On April 15, 2026, each of Helen S. Kim and Oleg Nodelman notified the Board of their decision to resign from their respective positions as members of the Board and all committees thereof, effective as of May 20, 2026. Ms. Kim and Mr. Nodelman's resignations are not due to any disagreement with the Company relating to any of the Company's operations, policies or practices.
- Charter amendmentJan 12, 2026
The Company filed its amended and restated certificate of incorporation (the 'Amended and Restated Certificate') with the Secretary of State of the State of Delaware. The Amended and Restated Certificate amends and restates the Company's existing sixth amended and restated certificate of incorporation, as amended, in its entirety to, among other things: (i) authorize 480,000,000 shares of Common Stock and 10,000,000 shares of Class A common stock; (ii) eliminate all references to the previously-existing series of preferred stock; (iii) authorize 10,000,000 shares of undesignated preferred stock; (iv) require the approval of at least two-thirds of the shares entitled to vote to remove a director for cause; (v) establish a classified Board; and (vi) eliminate the ability of the Company's stockholders to take action by consent in lieu of a meeting.
- Voluntary bankruptcyDec 17, 2024
The Notice informed the Company that, pursuant to the discretionary authority granted to Nasdaq under Listing Rule 5110(b), the Company's previously disclosed seeking of voluntary protection under chapter 11 of the United States Bankruptcy Code would serve as an additional basis for delisting the Company's common stock.
- Debt accelerationDec 16, 2024
The filing of the Bankruptcy Petitions described in Item 1.03 above constitutes an event of default under the indenture (the "Indenture"), dated June 9, 2022, among the Company, Akoustis, Inc., as guarantor, and The Bank of New York Mellon Trust Company, N.A., as trustee (the "Trustee"), governing the Company's 6.0% Convertible Senior Notes due 2027 (the "Convertible Notes"). As of December 16, 2024, the aggregate, principal amount of outstanding Convertible Notes was $44,000,000. Pursuant to the Indenture, upon the occurrence of this event of default, all of the outstanding Convertible Notes became due and payable immediately without further action or notice.
About Aktis Oncology
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
- Ticker
- AKTS
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Employees
- 79
- Listed
- Jan 9, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Aktis Oncology IPO price?
$18.00 a share.
When did Aktis Oncology go public?
Aktis Oncology listed on Nasdaq on Jan 9, 2026 under the ticker AKTS.
How much did the Aktis Oncology IPO raise?
$317.7M, before any underwriters' option.
How did Aktis Oncology open on its first day?
AKTS first traded at $27.00, +50.00% from the IPO price of $18.00.
How did AKTS close on its first day?
Its last regular-session trade was $22.19, +23.26% from the IPO price of $18.00.
What was the AKTS first-day trading range?
$19.33 to $29.16 in the regular session.
How many AKTS shares traded on the first day?
3.02M shares in the regular session.
How many shares did Aktis Oncology sell in its IPO?
17.65M shares.
How did AKTS do against the market on its first day?
AKTS fell 17.8% from its first trade to the last trade of the session. That is 18.0 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is AKTS listed on?
Aktis Oncology lists on Nasdaq under the ticker AKTS.
Build with Massive
Get the AKTS data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/AKTS/range/5/minute |
| Market cap | /v3/reference/tickers/AKTS |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.